Stage III: Definitive chemoradiotherapy

Frontiers of Radiation Therapy and Oncology

Volumn 42, Issue , 2010, Pages 122-134

  Fietkau, Rainer ^a   Semrau, Sabine ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; ESOPHAGITIS; HUMAN; INFECTION; INOPERABLE CANCER; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT INDICATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77949353402     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000262467     Document Type: Review

References (32)

1. Rolland E, Le Chevalier T, Auperin A, et al: Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): Two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs): A1-04. J Thor Oncol 2007;2(suppl 4):S309-S310.
2. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17: 2692-2699
3. Curran W, Scott C, Langer C, et al: Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Onc 2003;22:abstr 2499.
4. Fournel P, Robinet G, Thomas P, et al: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-5917.
5. Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98.
6. Belderbos J, Uitterhoeve L, van Zandwijk N, et al: Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007;43:114-121.
7. Auperin A, Rolland E; Curran W, et al: Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs): A1-05. J Thorac Oncol 2007; 28(suppl 4):S310.
8. Curran W, Scott C, Langer C, et al: Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000;19:abstr 1891.
9. Vokes EE, Herdon JE, Crawford J, et al: Randomized phase II study with gemicitabine or paclitaxel or vinorelbine as induction chemotherpy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and Leukemia Group B study 9431. J Clin Oncol. 2002; 20:4191-4198
10. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Klautke G, Fietkau R. 6-year experience of concurrent radiochemotherapy with vinorelbine plus a platinum compound in multimorbid or aged patients with inoperable non-small cell lung cancer. Strahlenther Onkol 2007;183:30-35.
11. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R: Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications: preliminary results. Strahlenther Onkol 2003;179:823-831.
12. Gadgeel SM, Ruckdeschel JC, Wozniak A, et al: Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients (pts). Proc Am Soc Clin Oncol 2008;26:abstr 7569.
13. Machtay M, Werner-Wasik M, DeNittis A, et al: Pilot study of carboplatin/radiotherapy plus 'dosedense' pemetrexed for locally advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 2008;26:abstr 7571.
14. Brade AM, Bezjak A, MacRae R, et al: A phase I study of concurrent pemetrexed (P)/cisplatin (C)/ radiation (RT) for unresectable stage IIIA/B nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008;26:abstr 7550.
15. Govindan R, Bogart J, Wang X, Liu D, Kratzke RA, Vokes EE: A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-Early evaluation of feasibility and toxicity. Proc Am Soc Clin Oncol 2008;26:abstr 7518.
16. Blumenschein GR, Paulus R, Curran WJ, et al: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial. Proc Am Soc Clin Oncol 2008;26:abstr 7516.
17. Vokes EE, Herndon JE, Kelley MJ, et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Nonsmall-cell lung cancer: cancer and leukemia group B. J Clin Oncol 2007;25:1698-1704
18. Kim S, Kim M, Choi E, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial. Proc Am Soc Clin Oncol 2007;25:abstr 7528.
19. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-2010.
20. Mina LA, Neubauer MA, Ansari RH, et al: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023-Updated results. Proc Am Soc Clin Oncol 2008;26:abstr 7519.
21. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26:2450-2456
22. De Ruysscher D, Botterweck A, Dirx M, et al: Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009;20:98-102.
23. Semrau S, Klautke G, Fietkau R: Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer following concurrent chemoradiotherapy: a single-center analysis of 161 cases. Submitted.
24. Semrau S, Klautke G, Virchow JC, Kundt G, Fietkau R. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir Med 2008;102:210-218.
25. Firat S, Byhardt RW, Gore E: Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002;54: 357-364.
26. Schild SE, Stella PJ, Geyer SM, et al: North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III nonsmall-cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206.
27. Atagi S, Kawahara M, Ogawara M, et al: Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol 2000;30:59-64.
28. Bursi F, Weston SA, Redfield MM, et al: Systolic and diastolic heart failure in the community. JAMA 2006;296:2209-2216.
29. Pelkonen M, Notkola IL, Nissinen A, et al: Thirtyyear cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006;130:1129-1137.
30. Firat S, Pleister A, Byhardt RW, Gore E: Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol 2006;29:252-257.
31. Cardenal F, Arnaiz MD, Isla D, et al: Randomized phase II study of sequential versus concurrent chemoradiotherapy (CRT) in poor-risk patients with inoperable stage III non-small cell lung cancer (NSCLC): Interim analysis. Proc Am Soc Clin Oncol 2004;22:abstr 7255.
32. Jennens RR, Giles GG, Fox RM: Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006;36:216-220.